DMX-200 for treating focal segmental glomerulosclerosis in people receiving angiotensin II receptor blocker therapy

DMX-200 is currently in clinical development for treating focal segmental glomerulosclerosis (FSGS) among patients who are also receiving an angiotensin II receptor blocker (ARB). FSGS is a rare disease in which scar tissue develops on the parts of the kidneys that filter waste from the blood (glomeruli). When the glomeruli become damaged or scarred, proteins begin leaking into the urine (proteinuria). Symptoms of FSGS include swelling in body parts, such as legs, ankles and around the eyes (oedema), weight gain, and foamy urine caused by proteins in the urine. However, many people with FSGS do not experience symptoms. If proteinuria remains elevated and kidney function continues to decline, patients progress to end stage kidney disease and require dialysis or kidney transplant. There remains a need for novel and improved treatments for FSGS.